[go: up one dir, main page]

EP2094661A2 - Procédé de préparation d'atazanavir - Google Patents

Procédé de préparation d'atazanavir

Info

Publication number
EP2094661A2
EP2094661A2 EP07848883A EP07848883A EP2094661A2 EP 2094661 A2 EP2094661 A2 EP 2094661A2 EP 07848883 A EP07848883 A EP 07848883A EP 07848883 A EP07848883 A EP 07848883A EP 2094661 A2 EP2094661 A2 EP 2094661A2
Authority
EP
European Patent Office
Prior art keywords
compound
atazanavir
preparation
methoxycarbonyl
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07848883A
Other languages
German (de)
English (en)
Inventor
Roberta Pizzocaro
Stefania Galimi
Alessia Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia Farmaceutici SpA
Original Assignee
Fidia Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA
Priority to EP07848883A priority Critical patent/EP2094661A2/fr
Publication of EP2094661A2 publication Critical patent/EP2094661A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom

Definitions

  • the present invention relates to a process for the preparation of Atazanavir.
  • Atazanavir ([3S-(3R*,8R*,9R*,12R*)]-3,12-bis(l,l-dimethylethyl)- 8-hydroxy-4,l l-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]- 2,5,6, 10,13-pentaazatetradecanedioic acid dimethyl ester)
  • (I) is a known antiviral agent and anti-HIV protease inhibitor, disclosed in EP 0 900 210 and in its equivalent US 5,849,911. These patents disclose preparation methods based on different synthetic approaches and intermediates; some of them are schematically represented and discussed below:
  • N-methoxycarbonyl-L-ferMeucine (1) is reacted with amino derivatives (2) and (3) respectively, while in scheme 3 epoxide (4) is reacted with hydrazine (5).
  • These processes suffer from some drawbacks and are difficult to carry out on an industrial scale.
  • N-methoxycarbonyl-L-terMeucine is very expensive; the synthesis of compounds (2) and (5) (schemes 1 and 3) is troublesome, with selectivity issues between the amino groups and compound (4) of scheme 3 is poorly stable.
  • the process of scheme 2 requires the use of a large excess of N- methoxycarbonyl-L-terMeucine (at least three equivalents); moreover, compound (3) is difficult to isolate and handle, and highly hygroscopic.
  • the present invention relates to a process for the preparation of Atazanavir (I)
  • Step a) is usually carried out in a mixture of a chlorinated solvent and an aprotic polar solvent, preferably selected from methylene chloride, chloroform and dimethylformamide, dimetylacetamide, DMPU, more preferably methylene chloride and dimethylformamide, in the presence of a condensing agent such as DCC, at a temperature of about 0 0 C, preferably between 0 and 5°C.
  • Step b) is usually carried out in methanol and ammonium formate and
  • step c) is carried out in a chlorinated solvent, preferably methylene chloride.
  • the compound of formula (6) can be prepared by reacting the hydrazine of formula (9)
  • the process of the invention is advantageous over the above-discussed prior art in that it avoids the use of amino-derivative (3) and it requires lower amounts of N-methoxycarbonyl-L-ferMeucine.
  • the filtrate was transferred into a one-liter round bottom flask and added with a solution of 33.6 g of K 2 HPO 4 -3H 2 O in 45 ml water at 0°-5°C, then 4-(pyridin-2- yl)benzylhydrazine was added keeping the temperature below 10 0 C and the resulting mixture was allowed to stand overnight.
  • the suspension was filtered and the organic layer was washed with water, with a solution of 27.5 g of NaH 2 PO 4 H 2 O in 45 ml water, and again with water, then separated and stirred with a solution of 12.1 g of 30% sodium hydroxide in 45 ml water.
  • the sodium hydroxide solution was discharged and the organic layer was washed in sequence with water, a sodium hydrogen phosphate solution (the same as above), water and brine, then separated and dried over sodium sulphate. After evaporation of the solvent under vacuum the title compound (18.5 g) was obtained as a yellowish solid.
  • Example 2 Preparation of t-Boc-protected compound (6)
  • epoxide (10) and 18.5 g of compound (9), prepared as described in example 1, were heated at 80 0 C for 48 hours in toluene (110 ml).
  • the reaction mixture was then cooled and filtered.
  • the solid was washed with toluene and dried to give 13.8 g of an off-white product.
  • Example 6 Preparation of Atazanavir Compound (8) (9.47 g), obtained according to example 5, was suspended in 200 mL of CH 2 Cl 2 , added with 1.99 g of diisopropyl ethylamine, and the resulting mixture was cooled to about O 0 C. 1.45 g of methyl chloroformate in 25 mL of CH 2 Cl 2 were added dropwise over about 2 hours. The suspension was then stirred for about half an hour at 0 0 C and added with an aqueous solution of 10% NaHCO 3 (100 mL) at O 0 C with vigorous stirring.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé de préparation d'Atazanavir, qui consiste à faire réagir le sel hydrochlorure du composé (6) avec de la N-methoxycarbonyl-L-tert-leucine, à enlever le groupe benzyloxycarbonyle et à faire réagir le produit obtenu avec du chlorure de methoxycarbonyle. Le procédé de l'invention est particulièrement avantageux en ce qu'il permet d'utiliser des quantités réduites de N-methoxycarbonyl-L-tert-leucine et d'éviter l'utilisation d'intermédiaires instables.
EP07848883A 2006-11-28 2007-11-13 Procédé de préparation d'atazanavir Withdrawn EP2094661A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07848883A EP2094661A2 (fr) 2006-11-28 2007-11-13 Procédé de préparation d'atazanavir

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06024597A EP1930324A1 (fr) 2006-11-28 2006-11-28 Procédé de préparation d'atazanavir
PCT/IB2007/003470 WO2008065490A2 (fr) 2006-11-28 2007-11-13 Procédé de préparation d'atazanavir
EP07848883A EP2094661A2 (fr) 2006-11-28 2007-11-13 Procédé de préparation d'atazanavir

Publications (1)

Publication Number Publication Date
EP2094661A2 true EP2094661A2 (fr) 2009-09-02

Family

ID=37906960

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06024597A Withdrawn EP1930324A1 (fr) 2006-11-28 2006-11-28 Procédé de préparation d'atazanavir
EP07848883A Withdrawn EP2094661A2 (fr) 2006-11-28 2007-11-13 Procédé de préparation d'atazanavir

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06024597A Withdrawn EP1930324A1 (fr) 2006-11-28 2006-11-28 Procédé de préparation d'atazanavir

Country Status (2)

Country Link
EP (2) EP1930324A1 (fr)
WO (1) WO2008065490A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272830A1 (fr) 2009-06-18 2011-01-12 Esteve Química, S.A. Procédé de préparation d'un dérivé d'azahexane hétérocyclique antiviral
US20130005780A1 (en) 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2013014633A1 (fr) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Procédé de préparation d'atazanavir ou de son sel bisulfate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008065490A3 *

Also Published As

Publication number Publication date
WO2008065490A2 (fr) 2008-06-05
EP1930324A1 (fr) 2008-06-11
WO2008065490A3 (fr) 2008-08-14

Similar Documents

Publication Publication Date Title
US8049009B2 (en) Process for the preparation of Tenofovir
JP6133931B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法
RU2114105C1 (ru) 4-(4-пиридил)бутиловый эфир n-сульфонилтирозина или его фармацевтически приемлемые соли и способ получения 4-(4-пиперидил)бутилового эфира n-сульфонилтирозина или его фармацевтически приемлемых солей
EP2094661A2 (fr) Procédé de préparation d'atazanavir
CN112272665B (zh) 制备立他司特的方法
JP2004520446A (ja) ロサルタンカリウムの結晶化方法
JP6816274B2 (ja) （ｓ）−ｎ１−（２−アミノエチル）−３−（４−アルコキシフェニル）プロパン−１，２−ジアミン三塩酸塩の製造方法
JP7252978B2 (ja) ２－（１－（ｔｅｒｔ－ブトキシカルボニル）ピペリジン－４－イル）安息香酸を調製するためのプロセス
JPS6272662A (ja) ４−アルコキシ−３−ピロリン−２−オン−１−イル−酢酸アルキルエステルおよびその製造方法
US20110040097A1 (en) Process for preparing lercanidipine hydrochloride
CN1251574A (zh) O－(3－氨基－2－羟基－丙基)－肟酰卤类的制备方法
US20120302759A1 (en) Combretastatin derivative preparation method
KR20020016617A (ko) 3ｓ-3-아미노-3-아릴 프로피온산 및 그의 유도체의 제조방법
JP3259191B2 (ja) ２，２′−アンヒドロアラビノシルチミン誘導体の合成法
JP7693921B2 (ja) プロリンアミド化合物の製造方法
EP0812842B1 (fr) Procédé pour la préparation de 5-(alkoxyméthyl)-2,3-pyridinedicarboximides
JP3127505B2 (ja) ピラゾロピリジン誘導体の製造法
JP2004238322A (ja) （ｒ）−３−アミノペンタンニトリルメタンスルホン酸塩の製造方法
JP4739695B2 (ja) ５−アミノ―１―置換―１，２，４―トリアゾールの製造方法、及び該製造方法で得られるトリアゾール誘導体
JP3719269B2 (ja) ２−アルキル−４−オキソ−５、６、７、８−テトラヒドロ−シクロヘプトイミダゾールの製造方法
JP3526606B2 (ja) Ｎ−置換ピラジンカルボキシアミドの製造方法
WO2005026119A1 (fr) Procede de production d'un compose indole contenant un sulfone amide
KR20040005897A (ko) 테트라치환된 이미다졸 유도체의 제조방법 및 그의 신규한결정 구조
KR20010040836A (ko) 항엽산제의 제조 방법 및 유용한 중간체
EP1508569A2 (fr) Procédé de préparation et nouvelle structure cristalline d'imidazoles tétrasubstituées

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090623

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20091113

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120707